Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity

Background. Chronic lymphocytic leukemia (CLL) is a b-cell tumor of small b-lymphocytes. In CLL, significant lymphocytosis (5000 monoclonal b-lymphocytes) is observed in the blood, there are no morphological signs of bone marrow involvement. The 2020 Russian Clinical Guidelines “Chronic lymphocytic leukemia/Small lymphocyte lymphoma” approved several main chemotherapy regimens for the treatment of CLL patients.
Aim. To perform a pharmacoeconomic analysis of the feasibility of fixed therapy regimens based on venetoclax in comparison with other targeted drugs registered in Russia, from the class of bruton kinase inhibitors, used until CLL progression or unacceptable toxicity.
Materials and methods. A list of direct costs in the health care system was compiled. To assess the change in the cost structure and budget impact analyze, 4 mathematical models were constructed from a health care system perspective. Model 1 analyzed the direct costs of the health care system over 5 years, without taking into account the addition of new patients to the model. At the beginning of the modeling, the patients were equally divided between the strategies; later, there was a natural withdrawal of patients from the cycle. Models 2–4 analyze the economic impact of increasing the proportion of venetoclax-based fixed regimens.
Results. with venetoclax + rituximab and venetoclax + obinutuzumab combinations used in 65 % of new patients, a cost reduction of 6.97 % would be observed in 2nd year of the budget impact analysis. In the case of an increase in the use of venetoclax in combination with rituximab or obinutuzumab to 80 % for new patients in the 5th year of the budget impact analysis, direct costs will decrease by 31.17 %, to 9,077,299,932 rubles.
Conclusion. Increasing the proportion of fixed-dose venetoclax-based combinations compared to regimens prior to CLL progression or unacceptable toxicity in all models demonstrates cost-effectiveness.

1. Miranda­Filho A., Piñeros M., Ferlay J. et al. Epidemiological patterns of leukaemia in 184 countries: a population­based study. Lancet Haematol 2018;5(1):e14–24. DOI: 10.1016/S23523026(17)30232­6

2. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).

3. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).

4. Watson L., Wyld P., Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008;81(4):253–8. DOI: 10.1111/j.1600­0609.2008.01114.x

5. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008;371(9617):1017–29. DOI: 10.1016/S0140­6736(08)60456­0

6. Hallek M., Cheson B.D., Catovsky D. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131(25):2745–60. DOI: 10.1182/blood­2017­09­806398

7. Russian clinical guidelines. Chronic lymphocytic leukemia/small lymphocyte lymphoma. 2020. (In Russ.).

8. Venetoclax. Instructions for medical use. Available at: https://grls.rosminzdrav.ru/. (In Russ.).

9. Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).

10. Malignant tumors in Russia in 2018 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2019. 250 p. (In Russ.).

11. Acalabrutinib. Instructions for medical use. Available at: https://grls.rosminzdrav.ru/. (In Russ.).

12. General Tariff Agreement of CHI of Saint Petersburg, 2022. Electronic resource. Available at: https://spboms.ru/page/docs. (In Russ.).

13. Rudakova A.V., Strugov V.V. The cost­effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab. Sovremennaya onkologiya = Journal of Modern Oncology 2019;21(2):29–32. (In Russ.). DOI: 10.26442/18151434.2019.2.190397

14. Nedogoda S.V., Salasyuk A.S., Barykina I.N. et al. Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. Sovremennaya onkologiya = Journal of Modern Oncology 2021;23(4):612–20. DOI: 10.26442/18151434.2021.4.201339